Related Experiment Video

Updated: Mar 16, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K

Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer

Raffaele Califano1,2, Keith Kerr3, Robert David Morgan4

  • 1Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UK. raffaele.califano@christie.nhs.uk.

Current Oncology Reports
|August 4, 2016
PubMed

Insights

Novel immunotherapies, like immune checkpoint inhibitors, offer new hope for treating non-small cell lung cancer (NSCLC). This review explores their effectiveness and patient selection strategies for advanced NSCLC.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Non-small cell lung cancer (NSCLC) presents significant treatment challenges with limited options for advanced stages.
  • High somatic mutational load in lung cancer enhances immune recognition of tumor cells.
  • Immune surveillance is critical for host defense against cancer, especially in NSCLC.

Purpose of the Study:

  • To review the efficacy of immune checkpoint inhibitors (ICIs) in treating NSCLC.
  • To describe the mechanism of action for ICIs in NSCLC.
  • To discuss strategies for selecting patients who will benefit most from ICI therapy.

Main Methods:

  • Review of recent clinical trial data on immune checkpoint inhibitors for NSCLC.
  • Analysis of the mechanism of action of ICIs.
  • Exploration of patient stratification methods for immunotherapy.

Main Results:

  • Immune checkpoint inhibitors demonstrate emerging efficacy as a treatment for NSCLC.
  • Clinical trial data supports the effectiveness of ICIs in NSCLC patients.
  • Strategies for patient selection are being developed to optimize treatment outcomes.

Conclusions:

  • Immune checkpoint inhibitors represent a promising therapeutic avenue for NSCLC.
  • Understanding ICI mechanisms and patient selection is key to improving outcomes in advanced NSCLC.
  • Further research into immunotherapy combinations and predictive biomarkers is warranted.
Keywords:
AtezolizumabCTLA-4DurvalumabImmune checkpointNivolumabNon-small cell lung cancerPD-1PD-L1Pembrolizumab

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K